Podcasts about new advances

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell, including the following topics: Introduction (0:00) Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05) Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06) Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O'Donnell (39:25) CME information and select publications

Luke O'Neill joins Pat to discuss three different stories this week focusing on advances in brain research, including an AI map of the brain and what it can do.

This episode is part of our oncology mini-series on VETchat by The Webinar Vet. Joining Anthony today is Owen Davies, RCVS, American and European specialist in veterinary oncology. In this episode, Anthony and Owen discuss some of the new advancements in oncology. Owen starts by sharing his career to date and then discusses some of the most recent advancements in oncology, such as those in screening tests and osteosarcoma treatment. They also talk about the use of liquid biopsies for early cancer detection, the challenges of treating feline lymphoma, and the potential of immunotherapy in cancer treatment.

For over a century, different surgical interventions have been explored to address symptoms of Parkinson's disease, and researchers are continuing to innovate and improve surgical treatments today. With new technology and an ever-expanding understanding of the function of the nervous system and the pathophysiology of Parkinson's disease, neurosurgical interventions are becoming more effective and more personalized. Dr. Doris Wang joins us in this episode to discuss her work using focused ultrasound and deep brain stimulation (DBS) as treatments for Parkinson's disease and other movement disorders. She discusses some of the benefits and limitations of focused ultrasound treatment, comparisons of traditional versus asleep interventional MRI-guided deep brain stimulation surgery, advances in adaptive deep brain stimulation, and the development of gait-related biomarkers that could drive adaptive DBS. Doris is a neurosurgeon and Associate Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF). This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

03-18-2024 J.L. Hancock Learn more about the interview and get additional links here: https://thedailyblaze.com/from-swarms-to-swarming-shocking-new-advances-in-warfare/ Subscribe to the best of our content here: https://priceofbusiness.substack.com/ Subscribe to our YouTube channel here: https://www.youtube.com/channel/UCywgbHv7dpiBG2Qswr_ceEQ

AI is enabling new strides in autonomous driving. In this episode, Azeem Azhar joins the co-founder and CEO of Wayve, Alex Kendall, to explore how the AI revolution is opening new market opportunities for the auto industry. Wayve is a UK-based start-up that makes AI technology for self-driving vehicles.

If you think you know all about the capabilities of drones, you don't know the half of it. In this podcast we explore the capabilities of drones to fly “inside of buildings” and not using GPS. My guest is Blake Resnick a technology star if there ever was one. We talk about the future of drone technology and the expected revisions to FAA rules and regulations which will open up the use of drones in so many different ways. We also do a deeper dive into his company BRINC and what their drones can do for public safety agencies. It is a very positive application of the technology.This episode is sponsored by AshBritt, a national rapid-response emergency management and logistics company. Celebrating its 30th year, AshBritt has led response efforts following 60 federally declared disasters across 30 states and has conducted more than 400 missions, successfully serving over 600 clients. AshBritt is the trusted emergency management contractor for cities, counties, states and for federal agencies, including the Department of Defense where AshBritt holds a pre-position debris management contract which covers 25 U.S. states.  Eric Holdeman is a professional emergency manager who is passionate about providing information that can help families, businesses & governments become better prepared for disasters of all types. Hear first hand expert insights from Eric on his Podcast, Blog & EricHoldeman.com.

Technology correspondent Paul Matthews joins Kathryn to look at some of the latest impressive advances brought to market in the last few years - including "electronic skin", storing energy as heat in a "sand battery" and biological storage. He'll also look at how Meta's Threads is going, one week on - how many users does it have and how's the feedback been? And as is often the way during tough economic times, there are also bargains to be had and many have come knocking on the door of Kiwi tech companies looking to make an acquisition. Paul is chief executive of CIO Studio.

Today we have our good friend and colleague Dr. Dominic D'Agostino returning for his third appearance on STEM-Talk. Dom, as most of our longtime listeners know, is well-known for his research into the ketogenic diet and the physiological benefits of nutritional ketosis. Since our last conversation with Dom in 2019, a tremendous body of research has been added to the literature about the therapeutic potential of ketosis. The high-fat, low-carb ketogenic diet has been linked to advances in the treatment of Alzheimer's, cancer, migraines, type-2 diabetes, psoriasis, sleep apnea, psychiatric disorders, traumatic brain injuries as well as a host of other diseases and disorders, which we cover in today's interview. In episode 14 of STEM-Talk, we talked to Dom about his development and testing of metabolic therapies involving the ketogenic diet for a wide range of diseases and conditions. In episode 87, Dom returned to reflect on his 10 years of research focused on the high-fat/low-carbohydrate diet. In today's interview, we talk to Dom about this latest work as well as his extensive research on hyperbaric oxygen. Dom is a tenured Associate Professor in the Department of Molecular Pharmacology and Physiology at the University of South Florida Morsani. He specializes in neuroscience, molecular pharmacology, nutrition, and physiology. Dom also is our colleague and a research scientist here at the IHMC. Show notes  [00:02:50] Dawn opens the interview mentioning Dom's recent IHMC Evening Lecture, in which he mentions the film “First Do No Harm” starring Meryl Streep. The film is based on the true story of a four-year-old boy diagnosed with severe epilepsy, whose extreme seizures continued despite extensive medical treatments. The boy's mother reached to Dr. John Freeman, a physician who had successfully treated patients with a ketogenic diet. Dawn asks Dom to give some context about this fictional film based on a true story. [00:05:05] Dawn asks Dom to discuss the many evidence-based applications of the ketogenic diet that he highlighted in his IHMC evening lecture. [00:07:11] Ken asks Dom about another story involving Russell Winwood, a man with severe chronic obstructive pulmonary disease, also known as COPD. Russell reached out to Dom with respect to treating his COPD with a ketogenic diet. [00:11:21] Ken asks if Russell only engaged in the ketogenic diet or if also used exogenous ketones. [00:12:10] Ken mentions that the ketogenic diet has the broad potential to be an anti-inflammatory diet. Ken goes on to mention that COPD is an inflammatory disease. As Dom's case report suggested, Ken wonders if the ketogenic diet has the potential to have strong therapeutic effects for other inflammatory conditions as well. Ken asks what other conditions Dom thinks might benefit from therapeutic ketosis. [00:14:02] Dawn mentions that Dom has been busy since his last appearance on STEM-Talk, having authored or collaborated on more than 40 papers, one of which garnered a lot of attention and was published in Frontiers in Neuroscience. This paper investigated whether therapeutic ketosis via ketone esters could represent a viable way to treat epilepsy and other seizure disorders. Dawn asks Dom to elaborate on this paper's findings and their significance. [00:16:26] Ken mentions that those listeners who are unfamiliar with ketone esters may want to check out our interview with Dr. Brianna Stubbs. Ken asks Dom to give a quick primer on ketone esters and why so many researchers in the field are excited about their potential. [00:19:20] Ken mentions that in addition to ketone salts and ketone esters, there are other product formulations out now, like the one from a company called Kenetik. Ken asks Dom what he thinks about this formulation. [00:23:33] Dawn mentions that Dom has had a number of animal studies published since 2019 looking at ketone induced neuroprotection and asks Dom to give an overview of some of this...

Shereen Siewert welcomes Paul Thomas, a professor in the Department of Physics and Astronomy at the University of Wisconsin – Eau Claire, and Wausau School District Planetarium Director Chris Janssen to discuss the latest in space exploration news and a preview of what to expect in the year ahead.

Merry Christmas to all of you Christmas-goers out there! Can you believe this is the last episode of According to RP for 2022? Thank you to all of our guests and supporters for a fantastic year! According to RP will be back in 2023! December is AIDS awareness month. With the world's focus being on COVID-19, many have forgotten that we have and still are fighting other healthcare crises. HIV/AIDS is one of them. In this episode, RP is chatting with the fabulous Dr. Cassandra Esperant, PharmD, AAHIVP. Dr. Esperant focuses on HIV prevention. Tune in as she talks about how HIV/ AIDS is still rampant, new advances in the prevention and maintenance of the disease, and hope for a future without HIV/ AIDS. To learn more about Dr. Cassandra and her amazing work. Follow her on Instagram @theprepandhivpharmacist and LinkedIn at Cassandra Esperant, PharmD, AAHIVP According to RP can be accessed everywhere you enjoy your podcasts!

2 part session: Join the following three physicians as they discuss new advances in treatment of uveal melanoma of the eye. This session was sponsored in part by Aura Biosciences. They discuss the following:  -RADIATION RETINOPATHY -Pars plana vitrectomy (PPV) with diode -ENDORESECTION -ADVANCES IN TREATMENT OF THE EYE (Aura presentation) Dr. Scott Walter, a practicing ophthalmologist in Hartford, Connecticut and is affiliated with Hartford Hospital.  Dr. David Reichstein, an ocular oncologist, who studied at the renowned Wills Eye Hospital here from Tennessee Retina. Dr. Peter Hovland, who specializes in vitreoretinal disease & surgery, and ophthalmology, here from Colorado Retina.   At Aura, our mission is to develop a new class of oncology targeted therapies that deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. Second half of episode: Understanding Genetics Testing with Castle Biosciences Join Dr. Reichstein, Dr. Hovland, and Dr. Walter for a discussion on genetics in uveal melanoma. This session is brought to you by Castle Biosciences. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. These tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. They believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information.  

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Russian forces have made new advances in eastern Ukraine - and are now close to encircling the strategic city of Severodonetsk.

Treatments for moderate-to-severe atopic dermatitis in children have made huge strides in recent months. Listen to Lawrence Eichenfield, MD, Emma Guttman-Yassky, MD, PhD, Candrice Heath, MD, and Minnelly Luu, MD discuss these advancements, what they mean for patients, and the importance of present and future research. This is a follow-up podcast to the https://pedraresearch.org/2020/09/25/2020-mod-severe-ad-ed/ (Emerging Therapies in the Treatment of Moderate-to-Severe Atopic Dermatitis in Children) educational series that aired in 2020. 

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

MIT Engineers Test An Idea For A New Hovering Rover | Brighter Side News (01:28) Due to the lack of atmosphere, the moon and other airless bodies such as asteroids can build up an electric field.Because of direct exposure to the sun and surrounding plasma. Moon's electric charge is strong enough to levitate dust more than 1 meter above the ground. Engineers at NASA and elsewhere have recently proposed harnessing this natural surface charge to levitate a gliderMylar wings, which is a material that holds the same charge as surfaces on airless bodies.  Thinking of magnets, the same charged sides would repel causing a levitation effect  A design would likely be limited to small asteroids, as larger planetary bodies would have a stronger, counteracting gravitational pull. Or would it?MIT's rover could get around this The concept resembles a retro-style, disc-shaped flying saucer, and uses tiny ion beams to both charge up the vehicle and boost the surface's natural charge.Generates a relatively large repulsive force between the vehicle and the ground with a small amount of power  In an initial feasibility study, the researchers show that such an ion boost should be strong enough to levitate a small, 2-pound vehicle on the moon and large asteroids. Large asteroid using a 10-kilovolt ion source The Moon the same rover would need a 50-kilovolt source Design relies on the use of miniature ion thrusters, called ionic-liquid ion sources Using a basic disc model with ion thrusters Could achieve levitation of about one centimeter off the ground Co-author Paulo Lozano explains why levitation on a rover would be good:“With a levitating rover, you don't have to worry about wheels or moving parts … An asteroid's terrain could be totally uneven, and as long as you had a controlled mechanism to keep your rover floating, then you could go over very rough, unexplored terrain, without having to dodge the asteroid physically.”   MIT unveils the world's longest flexible fiber battery. You can weave and wash it in fabrics | ZME Science (08:01) Engineers at MIT have created a rechargeable lithium-ion battery in the form of very long fiber.Could be used to 3D print batteries in any shape. The proof of concept is 140 meters long, making it the longest flexible fiber battery thus far.Length is arbitrary according to the engineers since they could do much longer lengths. Fiber batteries are not new, however previously they have all the lithium and other key materials outside the fiber, which would leave them unprotected.This Fiber is the opposite with the new system embedding the battery inside the fiber  This provides a protective outside coating, which gives the fiber both stability and waterproofing. The thickness of the fiber device is only a few hundred microns, much thinner than any previous attempts at a fiber battery. To demonstrate the functionality of this proof of concept, the researchers used the fiber battery to power a “Li-Fi” communications system, the kind that uses pulses of light to transmit data rather than radio waves. Includes a microphone, pre-amp, transistor, and diodes The 140-meter-long battery fiber has a rated energy storage capacity of 123 milliamp-hours  Enough to power a smartwatch or phone.  Battery fibers could be woven to produce two-dimensional fabrics like those used for clothing, but could also be used in 3-D printing to create solid objects, such as casings.Because the system creates it all without having to add anything else it would be one-step printing.   Scientists Can Now Print Metal Objects That Are Only 25 Nanometers Long | Interesting Engineering (13:08) A group of scientists has set a new benchmark in 3D printing by succeeding in fabricating ultrasmall metal objects using a new technique. According to the team, their system can be used to make objects out of copper just 25 billionths of a meter in diameter (equivalent to 25 nanometres).Equivalent to 195 copper atoms in a row. Their electrochemical 3D printing technique fabricates complex conductive structures with nanometer resolution, and it could have potential applications in battery technology, microelectronics, and sensor technology. The new electrochemical technique could be used to print far smaller metal objects that have never been printed before. Dr. Dmitry Momotenko of a chemist at the University of Oldenburg talked on the printing method with Phys.org:“The technology we are working on combines both worlds — metal printing and nanoscale precision … 3D-printed catalysts with high surface area and special geometry to allow particular reactivity could be prepared for the production of complex chemicals.” Momotenko and his team are currently working towards improving the efficiency of electrical energy storage through three-dimensional electrodes.     Smart sutures to monitor deep surgical wounds | MedicalXPress (17:24) Monitoring surgical wounds after an operation is an important step to prevent infection, wound separation and other complications. However, when the surgical site is deep in the body, monitoring is normally limited to clinical observations or costly radiological investigations that often fail to detect complications before they become life-threatening. To detect wound complications as soon as they happen, a team of researchers from National University of Singapore (NUS) have invented a smart suture that is battery-free and can wirelessly sense and transmit information from deep surgical sites. The NUS team's invention has three key components: a medical-grade silk suture that is coated with a conductive polymer to allow it to respond to wireless signals; a battery-free electronic sensor; and a wireless reader used to operate the suture from outside the body. These smart small sensors can monitor multiple problems (i.e. Wound integrity, gastric leakage and tissue micromotions), while also providing healing outcomes which are equivalent to medical-grade sutures.For example, if the suture is broken, an external reader picks up a reduced signal due to a reduction in the length of the smart suture's antenna, alerting the attending doctor to take action. One advantage of these smart sutures is that their use involves minimal modification of the standard surgical procedure.  Similar to existing sutures, clips and staples, the smart sutures may be post-operatively removed by a minimally invasive surgical or endoscopic procedure when the risk of complications has passed. Assistant Professor John Ho, who lead the team, commented on the smart sutures capability & the effect it would have: "Currently, post-operative complications are often not detected until the patient experiences systemic symptoms like pain, fever, or a high heart rate. These smart sutures can be used as an early alert tool to enable doctors to intervene before the complication becomes life-threatening, which can lead to lower rates of re-operation, faster recovery, and improved patient outcomes."  In future, the team is looking to develop a portable wireless reader to replace the setup currently used, enabling surveillance of complications even outside of clinical settings. Additionally they want to increase the detection capabilities for detecting wound bleeding and leakage after gastrointestinal surgery.   Researchers uncover protein that reverses muscle aging | Brighter Side News (23:13) A University at Buffalo-led research team has shown that a protein, NANOG, is effective at reversing aging in skeletal muscle cells. Skeletal muscles are organs of the vertebrate muscular system that are mostly attached by tendons to bones of the skeleton.Longer than in the other types of muscle tissue, and are often known as muscle fibers. In a series of experiments with mice, researchers overexpressed NANOG in myoblasts, which are the embryonic precursors to muscle tissue. The myoblasts were senescent, meaning they were no longer able to divide and grow. The overexpression improved some of the primary characteristics associated with age-related deterioration of cells, including autophagy, energy homeostasis, genomic stability, nuclear integrity and mitochondrial function.Autophagy - Bodies' way of clearing out damaged cells Additionally there was an increase in the number of muscle stem cells in the muscle of prematurely aging mice.Demonstrating the feasibility of reversing cellular aging in the body The study's corresponding author Stelios T. Andreadis, PhD stated:“Our work focuses on understanding the mechanisms of NANOG's actions in hopes of discovering druggable targets in signaling or metabolic networks that mimic the anti-aging effects of NANOG. Ultimately, the work could help lead to new treatments or therapies that help reverse cellular senescence, and aid the many people suffering from age-related disorders.”  ----more---- Podcast Links: Website: https://thatscoolnews.com/ Review The Podcast: https://thatscoolnews.com/review Email List: https://thatscoolnews.com/email Follow On Social Media: Instagram: https://www.instagram.com/thatscoolnews/ Twitter: https://twitter.com/Thats_Cool_News  Join the Community: Discord: https://thatscoolnews.com/discord Facebook Group: https://thatscoolnews.com/group  

Today, we're speaking with Dr. Neil Vasan, an assistant professor in the Department of Medicine, Division of Hematology Oncology at Columbia University Medial Center. Dr. Vasan is a physician scientist who studies how proteins function in breast cancer cell signaling and how treatments impact breast cancer cell signaling, which is the communication within a cell. His research has been published in top scientific journals including Science, Nature Cancer, Cancer Cell, and Cancer Discovery and he's received multiple awards, including being selected as a next gen star of the American Association for Cancer Research. Today, we're going to be discussing exciting new developments in the treatment of triple negative breast cancer. Dr. Vasan, welcome to the show!

In this guru addition host Lindsay Berra talks with Mike Boyle about his practical approach to strength coaching and fitness lifestyle. Author of New Advances in Functional Training, Mike is the founder of Mike Boyle Strength and Conditioning and he has strong opinions about the right way to do things. Previously he served as the Head Strength and Conditioning Coach at Boston University with a focus on Hockey. He also served as the Strength and Conditioning Coach for the Boston Bruins of the NHL and for the 1998 US Women's Olympic Ice Hockey Team, Gold Medalists in Nagano. One of the foremost experts in the fields of Strength and Conditioning, Performance Enhancement and general fitness he talks about what it takes to be healthy in today's world where the odds are clearly stacked against us. See omnystudio.com/listener for privacy information.

KSQD 7-19-2021: New advances for prostate cancer detection, including assessing severity, and therapies; Five minutes of intense constricted breathing as a therapy to reduce blood pressure and increase cardiac health; Email support for Dr. Dawn's comments about Coronavirus vaccines; POTS, postural orthostatic tachycardia syndrome, is often associated with viral infection, including Coronavirus; Dr Dawn reviews a good article in The Guardian (UK) about the microbiome, including the importance of dietary fiber; Lecithin a supplement to support brain function and clogged milk ducts; Raising core temperature is the best cure for Raynaud's syndrome; A new hypothesis for a cause of fibromyalgia based on antibodies; The problem of methamphetamine-associated cardiomyopathy; New research about bacterial vaginosis

KSQD 7-14-2021: New advances for prostate cancer detection, including assessing severity, and therapies; Five minutes of intense constricted breathing as a therapy to reduce blood pressure and increase cardiac health; Email support for Dr. Dawn's comments about Coronavirus vaccines; POTS, postural orthostatic tachycardia syndrome, is often associated with viral infection, including Coronavirus; Dr Dawn reviews a good article in The Guardian (UK) about the microbiome, including the importance of dietary fiber; Lecithin a supplement to support brain function and clogged milk ducts; Raising core temperature is the best cure for Raynaud's syndrome; A new hypothesis for a cause of fibromyalgia based on antibodies; The problem of methamphetamine-associated cardiomyopathy; New research about bacterial vaginosis

The science of walking is taking its next big step with the aid of a unique exoskeleton that allows users to walk further while using less energy. Developed by a multidisciplinary team from the Queen’s Faculty of Engineering and Applied Science, the backpack-mounted prototype removes energy during a specific phase of the gait cycle, lessening […]

Alzheimer’s disease is one of the most challenging conditions to manage due to the lack of disease-modifying treatment options. In this episode, Babak Tousi, MD discusses the developing therapies in Alzheimer’s disease management that may soon change the outlook for new and existing patients.

CME credits: 0.50 Valid until: 28-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/at-the-crossroad-of-care-new-advances-in-diabetic-kidney-disease/12092/ Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.

CME credits: 0.50 Valid until: 28-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/at-the-crossroad-of-care-new-advances-in-diabetic-kidney-disease/12092/ Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.

Dr. W.H. Wilson Tang provides an overview of novel approaches defining HFpEF and management strategies.

Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Bradley McGregor, MD, and Robert Motzer, MD, discuss first-line and second-line treatment options for advanced renall cell carcinoma on this episode of Oncology Data Advisor.

Concluding "The New Normal" series Pastors Jay and Mike discuss celebrating old methods while looking for new ways to share the message of hope.

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.Presenters:Natalie S. Callander, MDProfessor of Medicine  Director, Myeloma Clinical Program  University of Wisconsin Carbone Cancer CenterMadison, WisconsinShaji Kumar, MDDepartment of HematologyMayo ClinicRochester, MinnesotaContent based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.Link to full program, including associated downloadable slidesets: https://bit.ly/3gT324y

Part of understanding mental health and how to improve it for you and the people around you, is appreciating how it works, and what is possible. Eric Chapman and Amir Ali look at new advancements in brain research, and how we can physically change our brains, and develop new ways of thinking. It proves you really can teach an old dog new tricks.

New Advances in Brain Tumor Treatments and Trials with guest Dr. Zachary Corbin August 19, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

New Advances in Brain Tumor Treatments and Trials with guest Dr. Zachary Corbin August 19, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In the past year, Google has made quite a few changes to advance its Ad Platform. We've already seen Standard Text Ads being replaced with the much meatier Expanded Text Ads and now, the latest addition is Responsive Search Ads. Responsive Search Ads display up to three headlines consisting of 30 characters each, simultaneously. They also display up to two lines of description, consisting of 90 characters each – giving your ads over 80% more real estate on the SERP. In addition, with these multiple ad elements, Google employs its machine-learning skills to identify which elements of your ads are most effective over time. In today's The Big Idea podcast, Francois Lubbe speaks Christina Clapp about the benefits of using Responsive Search Ads as an additional tool for multivariate testing, as well as highlighting some its potential drawbacks.

New Advances in Stem Cell Transplant with guest Stuart Seropian, MD March 4, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

New Advances in Stem Cell Transplant with guest Stuart Seropian, MD March 4, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Immunotherapy is one of the most exciting areas of new discoveries and treatments for different kinds of cancer. Understanding how the immune system works is opening the doors to developing new treatments that are changing the way we think about and treat cancer. On this episode, guest host Linda House is joined by Dr. Gerald Messerschmidt to talk about immunotherapy and its new advancements in recent years. Elizabeth Franklin also joins the program to discuss barriers and access to quality care for patients with cancer.

Jason Hartman invites Patrick Cox on to the AMA show to talk about the Apple watch, stem cell technology, and why the FDA is holding back on amazing advances in the scientific and medical community. Patrick Cox specializes in the field of transformational technology and has worked closely with scientists all over the world. You can visit Patrick at PatrickCoxDNA.com to see him experimenting on himself and creating brand new muscle tissue.    Key Takeaways: 4:10 – There's a lot of scientific advances going on, but the media has always been bad at reporting science.  9:40 – Right now there are drugs that can cure common life-threatening diseases, but the government takes a long time to approve them.  15:10 – The FDA banned a natural product that reduced inflammation and one of Patrick's friends had a stroke because he couldn't take the plant anymore.  22:30 – If the FDA is the problem, what are other countries doing in the regenerative field?  26:00 – Patrick gives his opinion about the Apple watch.  28:00 – Big technology companies are supporting medical companies, which can help with a lot of roadblocks the medical/science community is currently experiencing   Mentioned In This Episode: http://www.patrickcoxdna.com/ https://www.mauldineconomics.com/